Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

he Company from Janssen under the collaboration and license agreement.Pharmacyclics, Inc.
Condensed Consolidated Statements of Operations(unaudited; in thousands, except per share data) Three Months EndedSix Months EndedDec. 31,Sep. 30,Dec. 31,Dec. 31, Dec. 31,20122012201120122011Revenue:  License and milestone revenue

$ 55,000$ 100,000$ 77,605$ 155,000$   77,605  Collaboration services revenue

2,9632,6952985,658335Total revenue

57,963102,69577,903160,65877,940Operating expenses*:  Research and Development

27,56719,07212,07646,63923,324  Less: Excess amounts related to Research and Development

(17,306)--(17,306)-Research and Development, net

10,26119,07212,07629,33323,324  General and Administrative

7,2254,8683,94412,0937,294  Less: Excess amounts related to General and Administrative

(819)--(819)-General and Administrative, net

6,4064,8683,94411,2747,294Total operating expenses

16,66723,94016,02040,60730,618Income from operations

41,29678,75561,883120,05147,322Interest and other income, net

77522112944Income before income taxes

41,37378,80761,904120,18047,366Income tax benefit (provision)

554(3,201)(5,651)(2,647)(5,651)Net income

$ 41,927$   75,606$ 56,253$ 117,533$   41,715Net income per share:Basic

$
.60$
.09$
.82$
.69$
.61Diluted

$
.56$
.02$
.78$
.58$
.58Weighted average shares used to computenet income per share:Basic

69,83969,51268,65869,67668,491Diluted

74,39974,45671,72574,40871,312* Includes share-based compensation as follows:Research and development

$   2,767$
2,590$   1,701$
5,357$
3,239General and administrative

1,5035766752,0791,301$   4,270$
3,166$   2,376$
7,436$
4,540Reconciliation of Selected GAAP Measures to Non-GAAP Measures (1) '/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q ... professional commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion ... by too quickly to process with the naked eye. , Slow motion ...
(Date:9/1/2015)... ... September 02, 2015 , ... Spirax Sarco , the leader in products ... Spirax Sarco Anytime. This platform, offering unique online ordering capabilities, is only available ... Log on to Spirax Sarco Anytime and within minutes you can be making ...
(Date:9/1/2015)... , Sept. 1, 2015 Prostate ... death in American men. One in seven ... 233,000 new cases are diagnosed annually. That said, ... using a powerful new technique, MRI Fusion Biopsy, ... large cancer lesions, treating only the affected areas ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... announced today that the National Institutes of Health (NIH) has awarded the company ... administered by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. ...
Breaking Biology Technology:Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Spirax Sarco Announces New Features to Anytime Platform 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3
... Nov. 3, 2010 Sangamo BioSciences, Inc. ... has been awarded a total of $978,000 in grants ... Discovery Project Program. Under the recently ... section 48D of the Internal Revenue Code, cash grants ...
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... Mass., Nov. 2, 2010 Repligen Corporation (Nasdaq: ... quarter of fiscal year 2011, ended September 30, 2010. ... to total revenue of $5,421,000 for the second quarter ... 35%.  Bioprocessing product revenue for the second quarter was ...
Cached Biology Technology:Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs 2Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs 3IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 2IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 3IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 4IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 5IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 6IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 7IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 8IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD 9Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 2Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 3Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 4Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 5Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 6Repligen Reports Second Quarter Fiscal Year 2011 Financial Results 7
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... Africa , August 24, 2015 ... Germany ,s largest biometrics manufacturer DERMALOG and its customized ... the "2015 African Biometrics Company of the Year Award". DERMALOG ... Nigeria .   -Cross reference: Picture ... http://www.presseportal.de/nr/8896 - On Thursday evening, in ...
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... by birds offer in several respects the nearest analogy to ... while contemplating how humans learned to speak. Language, he speculated, ... given rise to words expressive of various complex emotions." ... University of Tokyo, say that Darwin was on the right ...
... February 21, 2013 A new study published in ... Pathology suggests that cortical type 2 cannabinoid (CB2) ... ischemia. Researchers found that the cannabinoid trans-caryophyllene ... in both in vivo and in vitro animal models. ...
... certain catalyst materials work more efficiently when they are ... unclear. RUB chemists have now gleamed some initial answers ... charge states on the catalyst surface. "The catalyst and ... Professor Dominik Marx, depicting the underlying complex charge transfer ...
Cached Biology News:How human language could have evolved from birdsong 2How human language could have evolved from birdsong 3How human language could have evolved from birdsong 4Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury 2When water speaks 2
Request Info...
... TURBO DNase (patent pending) was developed using ... changes into the DNA binding pocket of wild-type ... of the protein for DNA. The result is ... Km for DNA, and an ability to maintain ...
Request Info...
Request Info...
Biology Products: